---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089936"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:05:16.964516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed

## Summary
- Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.
- Net loss $4.3M ($0.21 per share) vs $14.0M loss a year ago; operating loss $8.2M vs $11.4M.
- Closed up to $50M debt facility with OrbiMed; drew $25M at close; cash $16.5M at June 30.
- Warrant exchange completed; 79% of public warrants tendered, simplifying capital structure.
- Expects final Phase 1 data for nelitolimod in uveal melanoma and pancreatic cancer in Q4 2024.

## SEC filing metadata
- accession: 0001104659-24-089936
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465924089936/0001104659-24-089936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465924089936/tm2421775d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089936
- JSON: https://secwatch.observer/filing/0001104659-24-089936.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.